Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients

Marcin M. Gorski, Kevin Blighe, Luca A. Lotta, Emanuela Pappalardo, Isabella Garagiola, Ilaria Mancini, Maria Elisa Mancuso, Maria Rosaria Fasulo, Elena Santagostino, Flora Peyvandi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The development of neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) is the most problematic and costly complication of FVIII replacement therapy that affects up to 30% of previously untreated patients with severe hemophilia A. The development of inhibitors is a multifactorial complication involving environmental and genetic factors. Among the latter, F8 gene mutations, ethnicity, family history of inhibitors, and polymorphisms affecting genes involved in the immune response have been previously investigated. To identify novel genetic elements underling the risk of inhibitor development in patients with severe hemophilia A, we applied whole-exome sequencing (WES) and data analysis in a selected group of 26 Italian patients with (n=17) and without (n = 9) inhibitors. WES revealed several rare, damaging variants in immunoregulatory genes as novel candidate mutations. A case-control association analysis using Cochran-Armitage and Fisher's exact statistical tests identified 1364 statistically significant variants. Hierarchical clustering of these genetic variants showed 2 distinct patterns of homozygous variants with a protective or harmful role in inhibitor development. When looking solely at coding variants, a total of 28 nonsynonymous variants were identified and replicated in 53 inhibitor-positive and 174 inhibitor-negative Italian severe hemophilia A patients using a TaqMan genotyping assay. The genotyping results revealed 10 variants showing estimated odds ratios in the same direction as in the discovery phase and confirmed the association of the rs3754689 missense variant (OR 0.58; 95% CI 0.36-0.94; P 5 .028) in a highly conserved haplotype region surrounding the LCT locus on chromosome 2q21 with inhibitor development.

Original languageEnglish
Pages (from-to)2924-2933
Number of pages10
JournalBlood
Volume127
Issue number23
DOIs
Publication statusPublished - Jun 9 2016

Fingerprint

Exome
Hemophilia A
Genes
Factor VIII
Association reactions
Statistical tests
Chromosomes
Neutralizing Antibodies
Polymorphism
Mutation
Assays
Haplotypes
Cluster Analysis
Odds Ratio

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients. / Gorski, Marcin M.; Blighe, Kevin; Lotta, Luca A.; Pappalardo, Emanuela; Garagiola, Isabella; Mancini, Ilaria; Mancuso, Maria Elisa; Fasulo, Maria Rosaria; Santagostino, Elena; Peyvandi, Flora.

In: Blood, Vol. 127, No. 23, 09.06.2016, p. 2924-2933.

Research output: Contribution to journalArticle

@article{517f637a03c44b7595393364d2a60210,
title = "Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients",
abstract = "The development of neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) is the most problematic and costly complication of FVIII replacement therapy that affects up to 30{\%} of previously untreated patients with severe hemophilia A. The development of inhibitors is a multifactorial complication involving environmental and genetic factors. Among the latter, F8 gene mutations, ethnicity, family history of inhibitors, and polymorphisms affecting genes involved in the immune response have been previously investigated. To identify novel genetic elements underling the risk of inhibitor development in patients with severe hemophilia A, we applied whole-exome sequencing (WES) and data analysis in a selected group of 26 Italian patients with (n=17) and without (n = 9) inhibitors. WES revealed several rare, damaging variants in immunoregulatory genes as novel candidate mutations. A case-control association analysis using Cochran-Armitage and Fisher's exact statistical tests identified 1364 statistically significant variants. Hierarchical clustering of these genetic variants showed 2 distinct patterns of homozygous variants with a protective or harmful role in inhibitor development. When looking solely at coding variants, a total of 28 nonsynonymous variants were identified and replicated in 53 inhibitor-positive and 174 inhibitor-negative Italian severe hemophilia A patients using a TaqMan genotyping assay. The genotyping results revealed 10 variants showing estimated odds ratios in the same direction as in the discovery phase and confirmed the association of the rs3754689 missense variant (OR 0.58; 95{\%} CI 0.36-0.94; P 5 .028) in a highly conserved haplotype region surrounding the LCT locus on chromosome 2q21 with inhibitor development.",
author = "Gorski, {Marcin M.} and Kevin Blighe and Lotta, {Luca A.} and Emanuela Pappalardo and Isabella Garagiola and Ilaria Mancini and Mancuso, {Maria Elisa} and Fasulo, {Maria Rosaria} and Elena Santagostino and Flora Peyvandi",
year = "2016",
month = "6",
day = "9",
doi = "10.1182/blood-2015-12-685735",
language = "English",
volume = "127",
pages = "2924--2933",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "23",

}

TY - JOUR

T1 - Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients

AU - Gorski, Marcin M.

AU - Blighe, Kevin

AU - Lotta, Luca A.

AU - Pappalardo, Emanuela

AU - Garagiola, Isabella

AU - Mancini, Ilaria

AU - Mancuso, Maria Elisa

AU - Fasulo, Maria Rosaria

AU - Santagostino, Elena

AU - Peyvandi, Flora

PY - 2016/6/9

Y1 - 2016/6/9

N2 - The development of neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) is the most problematic and costly complication of FVIII replacement therapy that affects up to 30% of previously untreated patients with severe hemophilia A. The development of inhibitors is a multifactorial complication involving environmental and genetic factors. Among the latter, F8 gene mutations, ethnicity, family history of inhibitors, and polymorphisms affecting genes involved in the immune response have been previously investigated. To identify novel genetic elements underling the risk of inhibitor development in patients with severe hemophilia A, we applied whole-exome sequencing (WES) and data analysis in a selected group of 26 Italian patients with (n=17) and without (n = 9) inhibitors. WES revealed several rare, damaging variants in immunoregulatory genes as novel candidate mutations. A case-control association analysis using Cochran-Armitage and Fisher's exact statistical tests identified 1364 statistically significant variants. Hierarchical clustering of these genetic variants showed 2 distinct patterns of homozygous variants with a protective or harmful role in inhibitor development. When looking solely at coding variants, a total of 28 nonsynonymous variants were identified and replicated in 53 inhibitor-positive and 174 inhibitor-negative Italian severe hemophilia A patients using a TaqMan genotyping assay. The genotyping results revealed 10 variants showing estimated odds ratios in the same direction as in the discovery phase and confirmed the association of the rs3754689 missense variant (OR 0.58; 95% CI 0.36-0.94; P 5 .028) in a highly conserved haplotype region surrounding the LCT locus on chromosome 2q21 with inhibitor development.

AB - The development of neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) is the most problematic and costly complication of FVIII replacement therapy that affects up to 30% of previously untreated patients with severe hemophilia A. The development of inhibitors is a multifactorial complication involving environmental and genetic factors. Among the latter, F8 gene mutations, ethnicity, family history of inhibitors, and polymorphisms affecting genes involved in the immune response have been previously investigated. To identify novel genetic elements underling the risk of inhibitor development in patients with severe hemophilia A, we applied whole-exome sequencing (WES) and data analysis in a selected group of 26 Italian patients with (n=17) and without (n = 9) inhibitors. WES revealed several rare, damaging variants in immunoregulatory genes as novel candidate mutations. A case-control association analysis using Cochran-Armitage and Fisher's exact statistical tests identified 1364 statistically significant variants. Hierarchical clustering of these genetic variants showed 2 distinct patterns of homozygous variants with a protective or harmful role in inhibitor development. When looking solely at coding variants, a total of 28 nonsynonymous variants were identified and replicated in 53 inhibitor-positive and 174 inhibitor-negative Italian severe hemophilia A patients using a TaqMan genotyping assay. The genotyping results revealed 10 variants showing estimated odds ratios in the same direction as in the discovery phase and confirmed the association of the rs3754689 missense variant (OR 0.58; 95% CI 0.36-0.94; P 5 .028) in a highly conserved haplotype region surrounding the LCT locus on chromosome 2q21 with inhibitor development.

UR - http://www.scopus.com/inward/record.url?scp=84978221632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978221632&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-12-685735

DO - 10.1182/blood-2015-12-685735

M3 - Article

VL - 127

SP - 2924

EP - 2933

JO - Blood

JF - Blood

SN - 0006-4971

IS - 23

ER -